

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8260934

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the RECEIVING PARTY DATA TO AGOMAB THERAPEUTICS, FRANKLIN ROOSEVELTLAAN 348, 9000 GENT BELGIUM previously recorded on Reel 057124 Frame 0319. Assignor(s) hereby confirms the ASSIGNMENT.

CONVEYING PARTY DATA

Name	Execution Date
PAOLO MICHIELI	12/14/2018

RECEIVING PARTY DATA

Name:	AGOMAB THERAPEUTICS
Street Address:	FRANKLIN ROOSEVELTLAAN 348
City:	GENT
State/Country:	BELGIUM
Postal Code:	9000

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17397510

CORRESPONDENCE DATA

Fax Number: (801)355-0160

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 8012589816

Email: dmorath@patentlawworks.net, ktakahashi@patentlawworks.net

Correspondent Name: DANIEL J. MORATH, PH.D.

Address Line 1: 4516 SOUTH 700 EAST, SUITE 290

Address Line 4: SALT LAKE CITY, UTAH 84107-4221

ATTORNEY DOCKET NUMBER:	10763-09216-US
NAME OF SUBMITTER:	DANIEL J. MORATH, PH.D.
SIGNATURE:	/Daniel J. Morath, Ph.D./
DATE SIGNED:	11/06/2023

Total Attachments: 9

source=09216 US 2023-11-06 - Corrective Assignment#page1.tif

source=09216 US 2023-11-06 - Corrective Assignment#page2.tif

source=09216 US 2023-11-06 - Corrective Assignment#page3.tif

source=09216 US 2023-11-06 - Corrective Assignment#page4.tif

source=09216 US 2023-11-06 - Corrective Assignment#page5.tif
source=09216 US 2023-11-06 - Corrective Assignment#page6.tif
source=09216 US 2023-11-06 - Corrective Assignment#page7.tif
source=09216 US 2023-11-06 - Corrective Assignment#page8.tif
source=09216 US 2023-11-06 - Corrective Assignment#page9.tif

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
PAOLO MICIELI	12/14/2018
RECEIVING PARTY DATA	
Name:	AGOMAB THERAPEUTICS BVBA
Street Address:	PIETER VAN REYSSHOOTLAAN 2/104
Internal Address:	SINT-DENIJS-WESTREM
City:	GENT
State/Country:	BELGIUM
Postal Code:	9051
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17397510
CORRESPONDENCE DATA	
Fax Number:	(801)355-0160
Phone:	8012589816
Email:	dmorath@patentlawworks.net, ktakahashi@patentlawworks.net
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	DANIEL J. MORATH, PH.D.
Address Line 1:	310 EAST 4500 SOUTH, SUITE 400
Address Line 4:	SALT LAKE CITY, UTAH 84107
ATTORNEY DOCKET NUMBER:	10763-09216 US
NAME OF SUBMITTER:	DANIEL J. MORATH, PH.D.
Signature:	/Daniel J. Morath, Ph.D./

Date:	08/09/2021
	This document serves as an Oath/Declaration (37 CFR 1.63).
Total Attachments: 2 source=09216US_2021-08-09_CombinedAssignmentandDeclaration#page1.tif source=09216US_2021-08-09_CombinedAssignmentandDeclaration#page2.tif	
RECEIPT INFORMATION	
EPAS ID:	PAT6855405
Receipt Date:	08/09/2021

STATUTORY DECLARATION
FOR RECORDAL PURPOSE BEFORE PATENT OFFICES

I, Tim Knotnerus, do solemnly and sincerely declare and state as follows:

1. I, legal representative of the company named **AgomAb Therapeutics**, make this declaration in support of requests to record the following operations in respect of some patent applications and patents listed in the attached Schedule (and hereafter called "Patents"):

- Correction of a clerical error made on the name of the applicant from "AGOMAB THERAPEUTICS BVBA" to "AgomAb Therapeutics"
- Change of address of the head of office of this company occurred on 11 September 2019 from "Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem, 9051 Gent BELGIUM" to "Franklin Rooseveltlaan 348, 9000 Gent BELGIUM"

2. Indeed, regarding the clerical error, at the time of filing the Patents, the accurate name of our company was "AgomAb Therapeutics" (not "AGOMAB THERAPEUTICS BVBA")

3. However, due to a human and unintentional clerical error while preparing the filing orders, "AGOMAB THERAPEUTICS BVBA" was mentioned as corporate name of the applicant ("BVBA" being the acronym of the legal form at the time).

4. As such, the Patents are erroneously standing in the relevant Patent Registers in the name of "AGOMAB THERAPEUTICS BVBA", instead of "AgomAb Therapeutics".

5. On behalf of AgomAb Therapeutics, I now and hereby seek indulgence of the above-cited Patent Offices for correction of this clerical error made on the Patents and request update of the address of our company's head office to "Franklin Rooseveltlaan 348, 9000 Gent BELGIUM".

Declared in/Déclaré à: Ghent, Belgium

(In the presence of signature)

6/4/2020

This day of/ ce jour de: _____

(date of the signature)

By: Tim Knotnerus, CEO, AgomAb Therapeutics

DocuSigned by:

Knotnerus, Tim

A511753DEB354BD...

SCHEDULE

Office Code	Title	Priority	Filing Number	Filing Date (DD/MM/YYYY)	Publication Number	Publication Date (DD/MM/YYYY)	Grant Number	Grant Date (DD/MM/YYYY)	Expiration Date (DD/MM/YYYY)	Owner(s) corporate name	Owner(s) Address
QT	METHODS FOR PROMOTING PANCREATIC ISLET CELL GROWTH	IT 10201800 0000534,	PCT/EP2019/ 050084	03/01/2019	WO2019134 932	11/07/2019			03/07/2020	AGOMAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
QT	HGF-MET agonist for use in the treatment of cancer and colorectal fibrosis	IT 10201800 0000535,	PCT/EP2019/ 050077	03/01/2019	WO2019134 927	11/07/2019			03/07/2020	AGOMAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
EP	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	17735419.8	23/06/2017	3475302	01/05/2019			23/06/2037	AGOMAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
EP	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	19202060.0	08/10/2019					23/06/2037	AGOMAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
AU	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	2017288985	23/06/2017					23/06/2037	AGOMAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
BR	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	BR 11 2018 077139.2	23/06/2017						AGOMAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
CA	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	3.032.496	23/06/2017					23/06/2037	AGOMAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE

CN	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	20178004045 6.2	23/06/2017	CN 109689687 A	26/04/2019		23/06/2037	AGOMIAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
KR	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	10-2019-7002631	25/07/2017	10-2019-0025938	12/03/2019		23/06/2037	AGOMIAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
US	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	16/313,710	23/06/2017				23/06/2037	AGOMIAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
RU	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	2018146419	23/06/2017				23/06/2037	AGOMIAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
IN	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	20183704928 7	23/06/2017				23/06/2037	AGOMIAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
JP	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	2018-569021	23/06/2017	2019-524085	05/09/2019		23/06/2037	AGOMIAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
MX	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	MX/a/2019/00135	23/06/2017				23/06/2037	AGOMIAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE
NZ	ANTI-MET ANTIBODIES AND USES THEREOF	GB 1611123.9	749578	23/06/2017				23/06/2037	AGOMIAB THERAPEUTICS BVBA	Pieter van Reysschootlaan 2/104, Sint-Denijs-Westrem 9051 GENT BE

PATENT

REEL: 065473 FRAME: 0021

RECORDED: 07/25/2022

ANTI-MET ANTIBODIES AND USES THEREOF

**ASSIGNMENT AND DECLARATION UNDER 37 C.F.R. § 1.63
(For Use with Signed Application Data Sheet)**

Title of Invention: ANTI-MET ANTIBODIES AND USES THEREOF

Attorney Docket No.:

This assignment and declaration are directed to (check one):

- the attached application;
 the application identified by the title of invention given above and claiming priority of the patent application(s)

Country	Date	Application No.
United Kingdom	27/06/2016	1611123.9

United States Application or PCT International Application No. PCT/EP2017/065599, filed 23 June 2017.

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, as a below-named inventor I have sold and assigned, and hereby sell and assign, to:

Name of Assignee: AGOMAB THERAPEUTICS BVBA

Address of Assignee: Pieter Van Reysschootlaan 2/104, 9051 Sint-Denijs-Westrem (Ghent), Belgium

(hereinafter ASSIGNEE) all right, title, and interest in and to the above-identified invention and United States patent application, including : (i) any and all divisions or continuations thereof, and in and to any and all Letters Patent of the United States that may issue on any such application or for said invention, including any and all reissues or extensions thereof, to be held and enjoyed by said ASSIGNEE, its successors, or assigns to the full end of the term or terms for which any and all such Letters Patent may be granted; (ii) all applications for patents, utility models, and designs which may hereafter be filed for said invention in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said United States application under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable, to be held and enjoyed by said ASSIGNEE, its successors, or assigns to the full end of the term or terms for which any and all such patents, utility models, designs or other rights may be granted; and (iii) all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof, to be held and enjoyed by said ASSIGNEE, its successors, or assigns to the full end of the term or terms for which any and all such patents, utility models, designs or other rights may be granted.

I hereby authorize and request the Director of the U.S. Patent and Trademark Office to issue any and all such Letters Patent to said ASSIGNEE, its successors, or assigns in accordance herewith.

I warrant and covenant that I have the right to sell and assign the interests herein sold and assigned and that I have not executed and will not execute any document or instrument in conflict herewith.

I further covenant and agree that I will communicate to said ASSIGNEE, its successors, legal representatives, or assigns all information known to me relating to said invention or patent application and that I will execute and deliver any papers, make all rightful oaths, testify in any legal proceedings, and perform all other lawful acts necessary or desirable by said ASSIGNEE, its successors, legal representatives, or assigns to perfect title to said invention, to said application including divisions and continuations thereof and to any and all Letters Patent that may be granted therefor or thereon, including reissues or extensions, in said ASSIGNEE, its successors, or assigns, or to assist said ASSIGNEE, its successors, legal representatives, or assigns in obtaining, reissuing, or enforcing Letters Patent of the United States and any and all patents, utility models, designs or other rights that may be granted in the United States or of any country or countries foreign to the United States, for said invention.

ANTI-MET ANTIBODIES AND USES THEREOF

ASSIGNMENT AND DECLARATION UNDER 37 C.F.R. § 1.63
(For Use with Signed Application Data Sheet)

DECLARATION

As a below-named inventor, I hereby declare that:

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

Signature: *Paolo Micheli*

Inventor: MICHELI Paolo

Date: December 14, 2018

ANTI-MET ANTIBODIES AND USES THEREOF

**ASSIGNMENT AND DECLARATION UNDER 37 C.F.R. § 1.63
(For Use with Signed Application Data Sheet)**

Title of Invention: ANTI-MET ANTIBODIES AND USES THEREOF

Attorney Docket No.:

This assignment and declaration are directed to (check one):

- the attached application;
 the application identified by the title of invention given above and claiming priority of the patent application(s)

Country	Date	Application No.
United Kingdom	27/06/2016	1611123.9

United States Application or PCT International Application No. PCT/EP2017/065599, filed 23 June 2017.

ASSIGNMENT

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, as a below-named inventor I have sold and assigned, and hereby sell and assign, to:

Name of Assignee: AGOMAB THERAPEUTICS BVBA

Address of Assignee: Pieter Van Reysschootlaan 2/104, 9051 Sint-Denijs-Westrem (Ghent), Belgium

(hereinafter ASSIGNEE) all right, title, and interest in and to the above-identified invention and United States patent application, including : (i) any and all divisions or continuations thereof, and in and to any and all Letters Patent of the United States that may issue on any such application or for said invention, including any and all reissues or extensions thereof, to be held and enjoyed by said ASSIGNEE, its successors, or assigns to the full end of the term or terms for which any and all such Letters Patent may be granted; (ii) all applications for patents, utility models, and designs which may hereafter be filed for said invention in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said United States application under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable, to be held and enjoyed by said ASSIGNEE, its successors, or assigns to the full end of the term or terms for which any and all such patents, utility models, designs or other rights may be granted; and (iii) all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof, to be held and enjoyed by said ASSIGNEE, its successors, or assigns to the full end of the term or terms for which any and all such patents, utility models, designs or other rights may be granted.

I hereby authorize and request the Director of the U.S. Patent and Trademark Office to issue any and all such Letters Patent to said ASSIGNEE, its successors, or assigns in accordance herewith.

I warrant and covenant that I have the right to sell and assign the interests herein sold and assigned and that I have not executed and will not execute any document or instrument in conflict herewith.

I further covenant and agree that I will communicate to said ASSIGNEE, its successors, legal representatives, or assigns all information known to me relating to said invention or patent application and that I will execute and deliver any papers, make all rightful oaths, testify in any legal proceedings, and perform all other lawful acts necessary or desirable by said ASSIGNEE, its successors, legal representatives, or assigns to perfect title to said invention, to said application including divisions and continuations thereof and to any and all Letters Patent that may be granted therefor or thereon, including reissues or extensions, in said ASSIGNEE, its successors, or assigns, or to assist said ASSIGNEE, its successors, legal representatives, or assigns in obtaining, reissuing, or enforcing Letters Patent of the United States and any and all patents, utility models, designs or other rights that may be granted in the United States or of any country or countries foreign to the United States, for said invention.

ANTI-MET ANTIBODIES AND USES THEREOF

ASSIGNMENT AND DECLARATION UNDER 37 C.F.R. § 1.63
(For Use with Signed Application Data Sheet)

DECLARATION

As a below-named inventor, I hereby declare that:

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both.

Signature: *Paolo Michieli*

Inventor: MICHELI Paolo

Date: December 14, 2018